Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Repositionable transcatheter aortic valve system gains CE Mark

Direct Flow Medical : 10 January, 2014  (New Product)
Larger sized 29mm transcatheter aortic valve system with transfemoral delivery system gains CE mark for use in Europe
Repositionable transcatheter aortic valve system gains CE Mark


Direct Flow Medical, a transcatheter heart valve innovator focused on improving patient outcomes, has received CE Mark for the first fully repositionable 29mm transcatheter aortic heart valve, delivered through its flexible, 18 French transfemoral delivery system. The Direct Flow Medical valve is designed to virtually eliminate aortic regurgitation in all sizes of annulus by allowing complete assessment of hemodynamic performance and unlimited repositioning of the valve after full deployment in the native valve annulus. The approval expands the population of patients who can be treated using the Direct Flow Medical valve to patients with annulus sizes ranging from 21mm to 28mm.



“As with the smaller sizes of the Direct Flow Medical valve, the implantation of the 29mm valve is precise and fully controllable,” said Christoph Naber, MD, from the Contilia Heart and Vascular centre, Essen, Germany. “With this new valve size, a broader patient population will be able to benefit from the unique advantages of the Direct Flow Medical system.”



“Until now, patients with large annulus sizes who could not undergo surgical valve replacement had limited options, as other commercially available valves often leave significant aortic regurgitation at larger sizes and are not repositionable or retrievable,” said Bernard Lyons, President and CEO of Direct Flow Medical. “With the addition of the 29mm valve to our portfolio, we can now greatly improve outcomes for this group of patients, as well.”



The unique, double-ring design of the Direct Flow Medical valve conforms to the anatomy and creates a tight and durable seal around the annulus. The system is designed to improve long term survival of patients by resolving the clinical issues associated with current commercial valves. The system avoids rapid pacing of the heart during deployment, and does not require post-dilatation following placement, minimizing the risk of hemodynamic instability for patients. The Direct Flow Medical Transcatheter Aortic Valve System is indicated for the treatment of patients with severe aortic stenosis who are at extreme risk for surgical aortic valve replacement (SAVR).



Six month data from the DISCOVER CE Mark Trial, recently presented at the 2013 Transcatheter Cardiovascular Therapeutics (TCT) conference, confirm the system’s ability to virtually eliminate significant aortic regurgitation. Through six months, no patient experienced moderate or severe aortic regurgitation and there was a 96 percent overall survival rate, with 90 percent of patients in functional Class I or II. The system also demonstrated a strong safety profile, with a 97 percent VARC defined Combined Safety rate and no incidence of strokes (major or minor) or myocardial infarction in the evaluable cohort between 30 days and six months.



The Discover Trial is a prospective, multicentre study of the Direct Flow Medical system conducted at nine European sites in 100 patients with severe aortic valve stenosis who required replacement of their native aortic valve but were at extreme risk for open surgical repair.



The Direct Flow Medical portfolio now includes 25mm, 27mm and 29mm transcatheter aortic valves, all delivered through its flexible, 18 French delivery system, which have received the CE Mark and are currently commercially available in Europe.


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo